Pacira BioSciences, Inc.
PCRX· Nasdaq
Released Nov 5, 2026, after the close
10-Q filed Nov 5, 2026, 36 days after period end · 0001628280-26-071136
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $176.65M | $179.52M | $168.57M | $163.93M |
| Net Income | $28.52M | $5.43M | -$143.47M | $10.86M |
| EPS Diluted | $0.70 |
Pacira BioSciences, Inc. · CIK 1396814 · Engraved from SEC EDGAR
| $0.12 |
| -$3.11 |
| $0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.